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Alteration of Retinal Rod Outer Segment Membrane Fluidity in a Rat Model of
Smith-Lemli-Opitz Syndrome*
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is caused by an inherited defect in the last step in cholesterol (Chol)
biosynthesis, leading to abnormal accumulation of 7-dehydrocholesterol and decreased Chol levels.
Progressive retinal degeneration occurs in an animal model of SLOS, induced by treating rats with
AY9944, a selective inhibitor of the enzyme affected in SLOS. Here we evaluated alterations in the
biochemical and physical properties of retinal rod outer segment (ROS) membranes in this animal model.
At 1 month of AY9944 treatment, there were modest alterations in fatty acid composition, but no
significant differences in cis-parinaric acid (cPA) spectroscopic parameters in ROS membranes from
treated versus control rats. However, at 3 months, ROS docosahexaenoic acid (DHA) content was
dramatically reduced, and cPA fluorescence anisotropy values were decreased, relative to controls. Also,
1,6-diphenyl-1,3,5-hexatriene exhibited decreased rotational motion and increased orientational order in
ROS membranes from 3 month-old AY9944-treated rats, relative to controls. No significant changes in
protein:lipid ratios were observed; however, rhodopsin regenerability was compromised by 3 months of
treatment. These findings are consistent with reduced ROS membrane fluidity in the SLOS rat model,
relative to controls, primarily due to the dramatic reduction in membrane DHA levels, rather than altered
sterol composition.
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Alteration of retinal rod outer segment membrane fluidity
in a rat model of Smith-Lemli-Opitz syndrome
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Abstract Smith-Lemli-Opitz syndrome (SLOS) is caused
by an inherited defect in the last step in cholesterol
(Chol) biosynthesis, leading to abnormal accumulation of
7-dehydrocholesterol and decreased Chol levels. Progressive retinal degeneration occurs in an animal model of
SLOS, induced by treating rats with AY9944, a selective inhibitor of the enzyme affected in SLOS. Here we evaluated
alterations in the biochemical and physical properties of
retinal rod outer segment (ROS) membranes in this animal
model. At 1 month of AY9944 treatment, there were modest
alterations in fatty acid composition, but no significant differences in cis-parinaric acid (cPA) spectroscopic parameters in ROS membranes from treated versus control rats.
However, at 3 months, ROS docosahexaenoic acid (DHA)
content was dramatically reduced, and cPA fluorescence
anisotropy values were decreased, relative to controls. Also,
1,6-diphenyl-1,3,5-hexatriene exhibited decreased rotational
motion and increased orientational order in ROS membranes from 3 month-old AY9944-treated rats, relative to controls. No significant changes in protein:lipid ratios were
observed; however, rhodopsin regenerability was compromised by 3 months of treatment. These findings are consistent with reduced ROS membrane fluidity in the SLOS
rat model, relative to controls, primarily due to the dramatic
reduction in membrane DHA levels, rather than altered sterol
composition.—Boesze-Battaglia, K., M. Damek-Poprawa, D. C.
Mitchell, L. Greeley, R. S. Brush, R. E. Anderson, M. J.
Richards, and S. J. Fliesler. Alteration of retinal rod outer
segment membrane fluidity in a rat model of Smith-LemliOpitz syndrome. J. Lipid Res. 2008. 49: 1488–1499.
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Inborn errors of cholesterol (Chol) biosynthesis comprise a constellation of typically severe, often lethal, human
hereditary diseases having distinct genetic, biochemical,
and phenotypic characteristics, yet sharing the common
feature of abnormally low Chol levels in all tissues (as reviewed in Refs. 1, 2). The Smith-Lemli-Opitz syndrome
(SLOS) is an autosomal recessive disorder with associated
multiple congenital anomalies (3), and is caused by an enzymatic defect in the last step of the Chol biosynthetic pathway
(as reviewed in Ref. 4). The typical biochemical signature of
this syndrome is elevated levels of 7-dehydrocholesterol
(7DHC) together with reduced levels of Chol in blood and
other tissues, relative to the levels found in normal individuals. These abnormalities are the consequence of mutations in the DHCR7 gene, which encodes the enzyme
DHCR7 (3b-hydroxy-sterol-D7-reductase; EC 1.3.1.21) (4);
the mutant enzyme inefficiently catalyzes the conversion
of 7DHC to Chol. The central nervous system, in particular, is often profoundly affected in SLOS patients, as
manifested by moderate to severe mental retardation and
autism (1, 2, 4). Retinal dysfunction also appears to be an
associated feature of the disease, evidenced by rod photoreceptor electrophysiological defects (5).
A pharmacologically induced animal model of SLOS has
been developed by treating rats with AY9944, a selective
inhibitor of DHCR7 (6–8). We previously described a progressive (age-dependent) retinal degeneration in such an

Abbreviations: 7DHC, 7-dehydrochosterol; BRD, Brownian rotational diffusion; Chol, cholesterol; cPA, cis-parinaric acid; DHA, docosahexaenoic acid; DPH, 1,6-diphenyl-1,3,5-hexatriene; mAb, monoclonal
antibody; ROS, rod outer segment; SLOS, Smith-Lemli-Opitz syndrome.
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animal model, with associated biochemical, histological,
and electrophysiological abnormalities involving both rod
and cone photoreceptors (7, 8). By 1 postnatal month,
although retinal histology and electrophysiological competence in AY9944-treated rats appeared grossly unaffected,
the mole ratio of 7DHC:Chol in the retina was nearly
4:1, whereas the normal rat retina contains virtually no
7DHC (7). In striking contrast, by 3 postnatal months,
retinas of AY9944-treated rats had 7DHC:Chol mole ratios
typically .5:1, and exhibited concomitant histological degeneration along with rod and cone electrophysiological
abnormalities (8). Subsequently, in the course of lipidomic
analysis of whole retinas from age-matched control and
AY9944-treated rats, we recently documented a marked decline in docosahexaenoic acid (DHA; 22:6n3) content of
the major retinal glycerophospholipid molecular species
in the SLOS rat model, relative to controls (9). However,
under the conditions employed, the DHA levels in serum
and liver were not lower than those found in normal controls, indicating that there was no generalized, systemic n3
fatty acid deficiency.
In the present study, we performed subcellular fractionation of retinas from AY9944-treated and age-matched
control rats to obtain purified rod outer segment (ROS)
membranes, and then analyzed their fatty acid content
and membrane fluidity, the latter by fluorescence spectroscopy using two independent, naturally fluorescent probes:
cis-parinaric acid (cPA; 9Z,11E,13E,15Z-octadecatetraenoic
acid) and 1,6-diphenyl-1,3,5-hexatriene (DPH). These
linear fluorescent fatty acid probes are useful in detecting
and quantifying gel–fluid heterogeneity in lipid bilayers
(as reviewed in Ref. 10). cPA is a fluorescent n3 PUFA that
serves as one of the closest structural analogs to endogenous membrane lipids. This probe is routinely used to
evaluate molecular packing density and as a peroxidation
indicator (11). DPH, one of the most commonly used
fluorescent membrane probes, is an extremely hydrophobic, symmetrical, rod-like trans-polyene that penetrates
into the hydrophobic core of the bilayer, where its fluorescence intensity is over 10,000 times higher than in water
(as reviewed in Ref. 12). It is widely employed for assessing
membrane phase and fluidity using both steady-state and
time-resolved fluorescence spectroscopy. Time-resolved
measurements enable discrimination between simultaneous changes in probe lifetime, probe motion, and angular distribution in the membrane hydrophobic core. DPH
fluorescence lifetime is exquisitely sensitive to changes in
local dielectric properties, making it ideal for assessing
changes in transient water penetration into the membrane
(13), and time-resolved fluorescence depolarization of
DPH can provide detailed information about membrane
orientational order and dynamics (13, 14).
Here we show that the fluidity of ROS membranes is significantly reduced in the SLOS rat model, relative to controls, concomitant with the timing of retinal degeneration
in that model. We provide correlative evidence and a rationale that supports the conclusion that the marked
decrease in membrane lipid unsaturation, largely due
to losses in DHA, rather than to alterations in the sterol

profile, accounts for the altered membrane fluidity. Furthermore, the efficiency of rhodopsin regeneration is compromised in the SLOS rat model, relative to controls, even in
the presence of excess chromophore (11-cis retinaldehyde).
The results are discussed within the context of how such
changes may impact the efficiency of phototransduction
in the rod cell and the overall electrophysiological competence of the retina, with relevance to visual defects observed
in the SLOS rat model as well as in SLOS patients.

EXPERIMENTAL PROCEDURES
Materials
AY9944 (trans-1,4-bis(2-chlorobenzylamino-methyl)cyclohexanedihydrochloride) was custom synthesized, and matched the
spectroscopic and physical properties of an authentic sample
of AY9944 (kindly provided by Wyeth-Ayerst Laboratories,
Monmouth, NJ). All organic solvents were of HPLC grade, and
used as purchased from Fisher Scientific (Pittsburgh, PA). Fatty
acid standards were used as purchased from Nu-Chek
Prep, Inc. (Elysian, MN). Sterol standards were obtained from
Steraloids, Inc. (Newport, RI); 7DHC was periodically recrystallized from methanol-water and its purity verified by HPLC prior
to use. Anti-opsin monoclonal antibody (mAb 4D2) was a generous gift from Dr. Robert Molday (University of British Columbia,
Vancouver, BC). HRP-conjugated secondary antibodies were
obtained from Amersham Biosciences (Piscataway, NJ). Protein molecular weight standards were obtained from BioRad
(Hercules, CA). 11-cis Retinal was kindly provided by Dr. Rosalie
Crouch (Medical College of South Carolina, Charleston, SC). cPA
(9Z,11E,13E,15Z-octatetradecanoic acid) and DPH were purchased
from Molecular Probes/Invitrogen (Carlsbad, CA). Unless otherwise specified, all other reagents were used as purchased from
Sigma/Aldrich (St. Louis, MO). Alzet® osmotic pumps (Model
2ML4) were purchased from Durect Corporation (Cupertino, CA).

Animals
All procedures involving animals were approved by the Saint
Louis University IACUC and conformed to the National Institutes
of Healthʼs Guide for the Care and Use of Laboratory Animals and the
Association for Research in Vision and Ophthalmologyʼs Statement
for the Use of Animals in Ophthalmic and Visual Research. Adult
female Sprague-Dawley rats (pregnant, 6 days sperm-positive)
were obtained from Harlan (Indianapolis, IN). Rats were fed a
standard rat chow (Purina Mills TestDiet, Richmond, IN) and
were provided continuous access to water, ad libitum. In-house
analysis confirmed that the chow was essentially Chol-free (data
not shown). Rats were treated with AY9944 as previously described (8, 15). In brief, pregnant rats were implanted subcutaneously with Alzet® osmotic pumps containing AY9944 (in PBS
solution, 1.5 mg/ml), so as to provide continuous delivery of
AY9944 at a uniform rate (0.37 mg/kg/day, at 2.5 ml/h), beginning
on gestational day 7 and continuing through the second postnatal
week. Control dams received the same food and water ad libitum,
but received no other treatment. Starting on postnatal day 1, the
progeny of AY9944-treated dams were injected subcutaneously on
alternating days, three times per week, with AY9944 (30 mg/kg, in
PBS); treatment continued over a 3 month time course.

ROS membrane preparation
ROS membranes were prepared from dark-adapted rat retinas
(four pooled retinas per preparation) by discontinuous sucrose
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density ultracentrifugation, essentially as described previously
(16), with the modifications detailed in (17). All procedures were
performed in darkness or under dim red light (15W incandescent
light bulbs with Wratten #2 filters; Eastman Kodak, Rochester,
NY). Membranes were washed twice with ice-cold Tris-Mg buffer
(10 mM Tris-acetate, pH 7.4, containing 5 mM MgCl2) containing
diethylene triamine pentaacetic acid (0.1 mM), butylated hydroxytoluene (0.01 mg/ml), and SnCl2 (0.01 mg/ml) to retard lipid
peroxidation, by ultracentrifugation (Beckman TLA-45 rotor,
10 min at 100,000 g, 4°C; Beckman Optima-TL centrifuge;
Beckman Instruments, Palo Alto, CA). The membrane pellets
were resuspended by brief probe sonication in ice-chilled
HEPES-buffered saline (10 mM HEPES, pH 7.4, containing
100 mM NaCl) and flash frozen (in capped microcentrifuge tubes,
flushed with argon) in liquid nitrogen, then wrapped in aluminum
foil and stored in darkness at 280°C until used for analysis.

Rhodopsin regeneration studies
ROS membranes (resuspended in HEPES-buffered saline containing 10 mM hydroxylamine hydrochloride) were bleached by
continuous illumination using a light source equipped with an
orange filter, as previously described (18). Routinely greater than
90% of the total rhodopsin was bleached under these conditions.
In all experiments, the duration of bleaching was adjusted such
that the same total amount of rhodopsin was bleached in the
membranes being compared. The bleached membranes were
washed twice in 10 mM HEPES, pH 7.4 and centrifuged, and
the supernatant containing the excess hydroxylamine was discarded. Rhodopsin was regenerated from the apoprotein opsin
by the addition of a 2–3-fold molar excess of 11-cis retinal, prepared in ethanol, such that the final ethanol concentration was
0.5% (v/v). The samples were incubated in the dark at 37°C,
and aliquots were removed for spectrophotometric analysis
at 2.5, 4, and 24 h. The extent of rhodopsin regeneration was
measured spectrophotometrically as an increase in absorbance
at 500 nm, using a Perkin-Elmer Lambda 25 UV/Vis spectrophotometer (PerkinElmer Life and Analytical Sciences, Inc.;
Waltham, MA) equipped with a temperature-controlled microcuvette holder. The percent rhodopsin regenerated was calculated based on the amount of rhodopsin bleached in each
sample analyzed.

SDS-PAGE and immunoblotting
Detergent-solubilized ROS membranes from control and
AY9944-treated rats were prepared as described previously (19);
proteins were separated on 12% SDS-PAGE under reducing conditions and immunoblotted essentially per the method of
Towbin, Staehelin, and Gordon (20), normalized to total lipid
phosphorus load (1 mg) per lane. Western blots were probed
with a 1:1,000 dilution of mouse anti-opsin mAb 4D2, followed
by a 1:1,000 dilution of sheep anti-mouse, HRP-conjugated
secondary antibody. Immunoblots were visualized using an
enhanced chemifluorescence detection system (Amersham Biosciences; Arlington Heights, IL), which allegedly (per the manufacturer) provides better signal linearity than some commonly
used chemiluminescent detection systems. Digital analysis of blots
was performed using a Kodak Image Station 440CF. To determine
the relative amount of opsin present in each ROS membrane
specimen, the densitometric intensity of all of the immunostained components in each lane was determined and the total
value was normalized to total protein load (in micrograms).

Lipid phosphorus and protein quantification
Aliquots of resuspended ROS membranes were assayed for
total lipid phosphorus as described (21). Total protein content
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was determined using a micro-bicinchoninic acid kit, per the
directions of the manufacturer (Pierce; Rockford, IL).

RNA isolation and quantitative RT-PCR analysis
Total RNA was isolated using TRI reagent (Molecular Research
Center, Inc.; Cincinnati, OH). RNA yield was determined by
absorbance at 260 nm, and integrity was confirmed by gel electrophoresis. Total RNA (5 mg) was converted into cDNA using
the SuperScript® first-strand synthesis system for RT-PCR (Invitrogen). The cDNA samples were amplified in a Smart Cycler
(Cepheid, Inc.; Sunnyvale, CA) with LightCycler® Fast-Start
DNA Master SYBR Green I reagent (Roche Molecular Biochemicals; Mannheim, Germany), using specific primers (Sigma/
Aldrich). Gene expression was normalized using rat GAPDH
primers (F, forward primer; R, reverse primer): (F) gtcatcatctccgcccctt, (R) tttctcgtggttcacaccca. Specific primers for opsin and
peripherin/rds (per-2) were designed as follows: opsin, (F) gttcgtggtccacttcacca, (R) ttggagccctggtgggtaaa; per-2, (F) gggctgttcctgaagattga, (R) ggagcatgtcgatggtcttt. The results from RT-PCR
were obtained as crossing points, indicating the number of cycles
required for fluorescence of the PCR product to increase above
threshold value. These crossing points were converted to arbitrary
units of mRNA assuming a concentration-dependent straight line
for a semilog plot, with a value of 3.5 for the fold change in
mRNA/cycle (slope), and the crossing point cycle number with
no template as an estimate of the y-intercept. A final melt curve
from 60°C to 95°C was performed to confirm the specificity of
the PCR, and the identities of PCR products were checked
by gel electrophoresis. Results were compared using a two-way
ANOVA and Tukey test, with P , 0.050 indicating statistically
significant differences.

Membrane fluidity measurements
cPA studies. Membrane fluidity was determined from steadystate anisotropy measurements as described previously (22, 23).
cPA was introduced into ROS membrane by incubation of a
membrane suspension (5.0 ml) with cPA in ethanol such that
the final concentration of the fluorescent probe was 0.5 mol%
relative to membrane phospholipid. Samples were incubated
with probe or ethanol alone for 15 min at 37°C. Fluorescence
anisotropy assays the rotational diffusion of a molecule from
the decorrelation of polarization in fluorescence, i.e., between
the exciting and emitted (fluorescent) photons. Steady-state
fluorescence of cPA-containing ROS was recorded on a PerkinElmer LS55B spectrofluorimeter, equipped with polarizers, as
a function of increasing temperature (28–37°C). Fluorescence
intensity was recorded at lex 5 324 nm, lem 5 415 nm with
the excitation and emission slit-widths set at 10 and 5 nm,
respectively. Unlabeled ROS preparations were used as a
scattering blank. Fluorescence signal due to this scattering was
subtracted from cPA-containing samples.
Fluorescence anisotropy was calculated using the following equation:
Anisotropy(r) 5 (Iv 2 Ih )/(Iv 1 2Ih ),
where Iv is the intensity parallel to the excitation plane and Ih is
the emission perpendicular to the excitation plane.
DPH studies. Membranes were suspended in HEPES-buffered
saline at a phospholipid concentration of 0.15 mM. A DPH
stock solution was prepared in tetrahydrofuran, and 0.5 ml was
added to membrane suspensions at a phospholipid:DPH mole
ratio of 300:1. Fluorescence lifetime and differential polarization
measurements were performed with a K2 multifrequency cross-

correlation phase fluorometer (ISS; Urbana, IL). Excitation
at 351 nm was provided by an Innova 307 argon ion laser
(Coherent; Santa Clara, CA). Lifetime and differential
polarization data were acquired at 37°C at 15 modulation
frequencies, logarithmically spaced from 5 to 150 MHz. All
lifetime measurements were made with the emission polarizer
at the magic angle of 54.7° relative to the vertically polarized
excitation beam and with 1,4-bis(5-phenyloxazol-2-yl)benzene in
absolute ethanol in the reference cuvette. For each differential
polarization measurement, the instrumental polarization factors
were measured, found to be between 1.00 and 1.05, and the
appropriate correction factor applied. All measurements were
repeated with each sample a minimum of three times. Total
fluorescence intensity decays were analyzed with the sum of
three exponential decays. Reported values are the intensityweighted average, ,t., of the resulting three exponential time
constants. Measured polarization-dependent differential phases
and modulation ratios for each sample were combined with the
measured total intensity decay to yield the anisotropy decay, r(t).
All anisotropy decay data were analyzed using the Brownian
rotational diffusion (BRD) model (14, 24) and the results were
interpreted in terms of an angular distribution function of DPH,
C(u), which is symmetric about u 5 p/2. Relative phospholipid
acyl chain packing was quantified using the disorder parameter,
Cv, which is proportional to the overlap of the DPH orientational
probability distribution, C(u)sinu, with randomly oriented DPH
(24, 25). The BRD model quantifies probe motion in terms of the
diffusion coefficient for DPH rotation about its long axis, Dperp.
Fluorescence anisotropy decays were also analyzed using an
empirical sum-of-three-exponentials model. In this analysis,
probe orientation is summarized by the order parameter S,
where S 5 (r∞/ro)1/2 (26), and uncorrelated rotational motion is
characterized by the three rotational time constants, wi. The three
rotational time constants and their associated preexponential
factors were used to calculate the weighted average rotational
correlation time, ,w.. All analyses of time-resolved differential
polarization data were performed with NONLIN, with subroutines
specifying the fitting function written by one of the authors (D.C.M.).

Lipid extraction and fatty acid analysis
ROS membranes were protected from exposure to light as
much as possible throughout processing. After thawing, a mixture
containing known amounts of pentadecanoic acid (15:0), heptadecanoic acid (17:0), and heneicosanoic acid (21:0) was added to
each sample as internal standards, and total lipids were extracted
essentially per the Bligh–Dyer method (27), with minor modifications, as described previously (28). Lipid extracts were dried
under a stream of nitrogen, and fatty acids were derivatized to
form the corresponding methyl esters (FAMEs), prior to analysis
by gas–liquid chromatography, essentially as described previously
(28), with the following modifications. In brief, 0.20 ml of toluene
and 1 ml of 2% (by vol) methanolic sulfuric acid were added to
each lipid extract; the mixture was sealed in a glass tube under
nitrogen atmosphere with teflon-lined caps, vortexed, and heated
for 1 h at 100°C. After cooling on ice, 1.2 ml of water was added,
and the FAMEs were extracted three times with 2.4 ml of hexane,
then dried under nitrogen and dissolved in 20 ml nonane. Fatty
acid composition was then determined by injecting 3 ml of each
sample onto a DB-225 capillary column (30 m 3 0.32 mm I.D.;
J and W Scientific, Folsom, CA), using an Agilent 6890N gas chromatograph with a model 7683 autosampler (Agilent Technologies; Wilmington, DE), at an inlet temperature of 250°C and a
split ratio of 25:1. The column temperature was programmed
to begin at 160°C, ramped to 220°C at 1.33°C/min, and held at
220°C for 18 min. Hydrogen carrier gas flowed at 1.6 ml/min,

and the flame ionization detector temperature was set to
270°C. The chromatographic peaks were integrated and processed with ChemStation® software (Agilent Technologies).
FAMEs were identified by comparison of their relative retention
times with authentic standards, and relative mole percents were
calculated. Multivariant ANOVA with post-hoc Scheffe tests were
used to determine statistical significance, with a maximum cutoff of P , 0.05.

Sterol analysis
Verification of sterol composition was achieved by reversephase HPLC, after saponification and extraction of the nonsaponifiable lipids, as described elsewhere (7, 8). In brief, aliquots
of resuspended ROS membranes were saponified in methanolic
KOH, and the nonsaponifiable lipids were extracted with petroleum ether, redissolved in methanol, and analyzed by reversephase HPLC (mobile phase: methanol; detection at 205 nm).
An internal standard of [3H]cholesterol (?1 3 105 dpm) was
added to each specimen prior to saponification and extraction.
Quantitative analysis of sterols was performed in comparison with
authentic standards of pure 7DHC and Chol; integrated peak
areas were analyzed with respect to empirically determined
response factors for each sterol, with calculated masses corrected
for recovery efficiency of the internal [3H]cholesterol standard.
This system permits baseline separation of 7DHC and Chol, with
a lower detection limit of ?10 pmol.

RESULTS
AY9944 treatment causes significant alteration in
sterol synthesis
Initially, we confirmed that AY9944 had produced the
desired and expected effect on sterol metabolism in the
rat under the given treatment conditions, which would
be reflected in the abnormal steady-state accumulation
of 7DHC and reduction of both Chol levels as well as total
sterol levels in serum (Table 1). This expectation was met:
after 1 month of AY9944 treatment, the 7DHC:Chol molar
ratio in serum was 2.0 and total sterols were only 16.4% of
control values; by 3 months of AY9944 treatment, the
7DHC:Chol molar ratio was 4.6, and the total sterols were
TABLE 1. Sterol composition and content of serum and ROS
membranes from AY9944-treated and control rats
Treatment
Group

Age

month (N)
Serum

ROS

Control
1AY9944
Control
1AY9944
Control
1AY9944
Control
1AY9944

1
1
3
3
1
1
3
3

(7)
(19)
(12)
(16)
(4)
(6)
(6)
(4)

7DHC:Chol

mole ratio
0
2.0
0
4.6
0
3.5
0
5.6

6 0.8
6 1.0

Total Sterols

Control

mg/dl

%

6
6
6
6

100
16.4
100
21.8

100.5
16.5
95.5
20.8

10.7
6.2
17.5
5.6

6 0.4
6 1.6

7DHC, 7-dehydrocholesterol; Chol, cholesterol; ROS, rod outer
segment. Aliquots (50 ml each) of serum or ROS membranes (resuspended in buffer) were saponified in methanolic KOH, and the nonsaponifiable lipids were extracted with petroleum ether, evaporated to
dryness, redissolved in methanol, and analyzed by reverse-phase HPLC.
Values represent the mean 6 SD, with number of biologically independent samples (N) given in parentheses, corrected for recovery efficiency using an internal standard of [3H]cholesterol.
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21.8% of control values. In control rats, 7DHC levels were
below the limit of detection using the HPLC method employed (,10 pmol), so the 7DHC:Chol ratio is 0 in control
serum. A similar analysis of ROS membrane sterols revealed that the 7DHC:Chol molar ratio was 3.5 after
1 month of AY9944 treatment, and after 3 months, the
ratio had increased 1.6-fold (P , 0.05) to 5.6. There was
no detectable 7DHC in control ROS preparations. These
findings are in good agreement with the results of our
prior studies (7, 8) and confirm that the effects of AY9944
were as expected and increased with duration of exposure.
AY9944 treatment causes profound perturbation of ROS
membrane fatty acid composition
The results of the comparative fatty acid analysis of ROS
membranes at 1 and 3 postnatal months as a function of
AY9944 treatment are shown in Fig. 1. Here, the values
are expressed as relative mole percent of the total recovered
fatty acid. In good agreement with reports by others (as
reviewed in Ref. 29), the major ROS membrane fatty acid
species are 22:6n3 .. 18:0 . 16:0 .. 18:1 ?20:4n6. As
shown in Fig. 1A, after 1 month of AY9944 treatment, there
was no statistically significant reduction in the level of
22:6n3 (DHA), compared with that found in ROS membranes from age-matched control rats. However, there
was a 3.6-fold increase in the levels of 22:5n6 in ROS
membranes from AY9944-treated rats, relative to controls

(5.8 mol% vs. 1.6 mol%, respectively; P , 0.05), but the
mass of 22:5n6 is relatively minor, especially when compared with that of 22:6n3. Several other fatty acid species
exhibited alterations as a function of AY9944 treatment
compared with controls; however, the magnitude of these
changes, as well as their mass (relative mole percent), was
relatively small. The ratio of n6 to n3 fatty acids was 0.60 6
0.02 for ROS membranes from AY9944-treated rats, versus
0.39 6 0.10 for controls, but this difference was not statistically significant (P . 0.05). After 3 months of AY9944 treatment (Fig. 1B), there was a significantly lower level of
22:6n3 in ROS membranes compared with age-matched
controls (24.9 mol% vs. 39.4 mol%; 1.58-fold difference,
P , 0.05); this was accompanied by a 4.5-fold higher level
of 22:5n6 (5.4 mol%) compared with age-matched controls
(1.2 mol%; P , 0.001). The n6:n3 ratio was 0.52 6 0.05
for ROS membranes from AY9944-treated animals, versus
0.22 6 0.09; this 2.36-fold difference was highly significant
(P , 0.001). Perhaps more informative is the saturation
index, Rs, which we define as the ratio of saturated fatty acid
species to PUFAs (defined here as any fatty acid containing
two or more double bonds). After 1 month of AY9944 treatment Rs was 0.89 versus 0.91 for age-matched controls (i.e.,
only a ?2% difference), whereas after 3 months of treatment, Rs was 1.27 versus 1.13 for age-matched controls
(a ?12% difference). More importantly, if we compare
the Rs value at 1 versus 3 months of AY9944 treatment, there
was a ?1.4-fold increase in the saturation index of ROS
membrane lipids, which would predict a significant
decrease in membrane fluidity as a function of increasing
time of exposure to AY9944.
If one normalizes the levels of three prominent resident
ROS membrane PUFAs (20:4n6, 22:5n6, and 22:6n3) to
the levels of stearic acid (18:0), which do not vary as a function of AY9944 treatment, the following information is
revealed (Table 2). At 1 month of AY9944 treatment, the
normalized levels of arachidonic acid (20:4n6) modestly
increased (by about 16%), relative to controls, and this
change was statistically significant (per data in Fig. 1;
P , 0.05), whereas by 3 months, the apparent change in
the relative level of this fatty acid was not statistically significant. The normalized levels of 22:6n3 (DHA) after
1 month of AY9944 treatment were not statistically different from those of age-matched control membranes, but
then dramatically decreased (by ?41%, P , 0.05), relative
TABLE 2. Normalized PUFA content of ROS membranes from
control and AY9944-treated rats
1 Month Normalized Value
Fatty Acid

Control

1AY9944

Change

0.286
0.067
1.44

0.333
0.233
1.19

116.4a
1348a
217.9b

3 Months Normalized Value
Control

1AY9944

Change

0.181
0.041
1.39

0.155
0.180
0.825

214.4b
1439a
240.6a

%

Fig. 1. Fatty acid profiles of retinal rod outer segment (ROS)
membranes from AY9944-treated (filled bars) and control (open
bars) rats at (A) 1 and (B) 3 postnatal months of age. Values are
mean 6 SD (N 5 3), expressed as relative mole percent. * Statistical
significance (P , 0.05; multivariant ANOVA with post-hoc Scheffe
test) of differences between treated and control values for a given
fatty acid species.
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20:4n6
22:5n6
22:6n3

%

Data are average values, obtained by dividing the relative mol%
values (see Fig. 1) of the given fatty acid species by the relative mol%
of stearic acid (18:0).
a
Statistically significant (P , 0.05; N 5 3).
b
Not statistically significant (P . 0.05; N 5 3).

to age-matched controls, after 3 months of AY9944 treatment. The normalized levels of eicosapentaenoic acid
(22:5n6) exhibited a marked (almost 3.5-fold) increase
after 1 month of AY9944 treatment, relative to controls,
with an even larger (4.4-fold) elevation occurring after
3 months of treatment (P , 0.05). Again, it should be appreciated that whereas DHA represents the major fatty
acid in ROS membranes, 20:4n6 and 22:5n6 represent
quantitatively minor species, normally accounting for only
about 5–6 mol% and 2–3 mol%, respectively, of the total
fatty acid content of ROS membranes (29). Thus, although
the apparent changes in the levels of these minor fatty
acids may be statistically significant, it is unlikely that such
changes would significantly impact the physical properties
of the membranes. However, the large decrease in DHA
content at 3 months would be expected to have significant
consequences on membrane properties (see Discussion).
These changes are also consistent with our recent observations concerning reduced levels of DHA in whole retinas of
rats treated with AY9944, relative to age-matched controls (9).
AY9944 treatment does not alter the lipid:protein ratio or
opsin content of ROS membranes
The visual pigment apoprotein opsin accounts for at
least 90% of the total integral membrane protein content

of ROS membranes (as reviewed in Ref. 29). To assess
whether AY9944 treatment had any effect on protein
packing density in ROS membranes, we measured lipid
phosphorus and total protein in ROS membranes from
treated and control rats, and also performed quantitative
immunoblot analysis of those membranes, using monospecific antibodies (mAb 4D2) against opsin. The average
phospholipid:protein ratios were not appreciably different in ROS membranes prepared from AY9944treated rats [N 5 2: 1 month, 58 (range, 53.1–62.9); and
3 months, 56 (range, 52.3–59.7)] compared with controls
[1 month, 55 (range, 54.7–60.3); and 3 months, 57 (range,
52.2–61.8)]. Also, Western analysis (Fig. 2A, B) of ROS
membranes prepared from 1 and 3 month-old, AY9944treated and age-matched control rats showed no apparent
differences in the levels of opsin as a consequence of
AY9944 treatment. Consistent with this, we also found
no effect of AY9944 treatment on opsin mRNA expression
levels (by quantitative RT-PCR) (Fig. 2C), or on mRNA
expression levels of peripherin/rds, another ROS resident
membrane protein (data not shown). Taken together,
these data suggest that AY9944 treatment does not appreciably alter the protein packing density in ROS membranes or alter opsin expression or incorporation into
ROS membranes.

Fig. 2. Opsin protein levels in control (C) and AY9944treated (AY) rat ROS membranes. A: Western blot probed
with monoclonal anti-opsin antibodies (mAb 4D2). Samples were adjusted in order to load an equivalent amount
(1 mg total) of lipid phosphorus per lane. Immunoreactivity
was visualized using HRP-conjugated secondary antibodies
and enhanced chemifluorescence detection. Migration positions of protein molecular weight markers (Mr in kDa) are
indicated at left. B: Quantitative densitometric analysis of
Western blots. Graph represents measurements (mean 6
SD) obtained from four independent blots per treatment
and time point (1 and 3 months). C: Quantitative RT-PCR
analysis of opsin expression in retinas isolated from control
and AY9944-treated rats. Graph shows values (mean 6 SD,
N 5 4) expressed in arbitrary units.

ROS membrane fluidity in the SLOS rat model

1493

AY9944 treatment causes alterations in the physical
properties of ROS membranes
Given the fact that there were dramatic alterations in
the sterol and fatty acid profiles of ROS membranes as a
consequence of AY9944 treatment, we evaluated whether
the physical properties of the membranes also were altered
by such treatment. A comprehensive examination of the
effects of treatment with AY9944 on acyl chain packing (fluidity) in ROS membranes was performed utilizing
steady-state fluorescence anisotropy of cPA and fluorescence lifetime and anisotropy decay measurements of
DPH. These two fluorescent probes partition into different
parts of a fluid phase membrane, with cPA anchored to
the interface whereas DPH is free to partition into the center of the bilayer, where its orientation will reflect the
free volume resulting from the degree of acyl chain packing order (10).
When used at a suitably low concentration, cPA is sensitive to changes in membrane order in the interfacial
region. We compared the fluorescence anisotropy of cPA
in ROS membranes from control and AY9944-treated rats
in vitro as a function of age (1 vs. 3 months) at 37°C.
The results are shown in Fig. 3. ANOVA analysis of the
anisotropy data revealed no statistically significant alteration in fluorescence anisotropy in ROS membranes from
1 month-old AY9944-treated rats, relative to age-matched
controls. However, at 3 months of age, there was a modest
(?14%) decline in the anisotropy in ROS from AY9944treated rats, relative to controls, which was statistically significant (P 5 0.0068, N 5 4), consistent with an increase in
fluidity in the interfacial region.
We performed a follow-up analysis of ROS membranes
from 3 month-old AY9944-treated and control animals,
using DPH as the fluorescent membrane probe. DPH

Fig. 3. Steady-state anisotropy measurements of cis-parinaric
acid (cPA) in purified ROS membranes from 1 and 3 month-old
rats. Open bars, controls; filled bars, AY9944-treated. Values are
mean 6 SD (N 5 4), measured at 37°C. * Statistically significant
difference (P 5 0.0068) between treated versus control samples
at 3 months of age.
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fluorescence is efficiently quenched by water; hence,
DPH fluorescence lifetime in a membrane is indicative
of relative water penetration (13). In control ROS membranes at 37°C, the intensity-weighted average fluorescence lifetime, ,t., was 9.36 6 0.05 ns, whereas in ROS
membranes from AY9944-treated animals, it was significantly lower (9.17 6 0.1 ns; P 5 0.017). This numerically
modest (?2%) yet statistically significant decrease in fluorescence lifetime is consistent with the interpretation that
the headgroup region in the treated membranes is more
loosely packed with respect to permitting transient water
penetration. Taken together with the change in cPA fluorescence anisotropy, these results indicate that the interfacial and headgroup regions of the membrane are more
disordered in the ROS membranes from AY9944-treated
rats, compared with ROS membranes from age-matched
control rats.
The decay of DPH fluorescence anisotropy reflects the
influence of acyl chain packing on DPH motion and orientational order in the hydrophobic core of the membrane
(13, 14). As shown in Fig. 4, in this region, the ROS membranes from AY9944-treated rats exhibited increased acyl
order relative to age-matched (3 month-old) controls.
The BRD model explicitly separates the distinct effects
of probe orientational order and probe motion on the
dynamics of fluorescence depolarization. The DPH oriental distribution is summarized by the disorder parameter

Fig. 4. Measures of acyl chain ensemble order (membrane fluidity) obtained from analysis of 1,6-diphenyl-1,3,5-hexatriene (DPH)
fluorescence anisotropy decays. A: The free volume (or disorder
parameter), fv, from analysis via the Brownian rotational diffusion
(BRD) model. The smaller value for the membranes from AY9944treated animals, compared with controls, indicates decreased acyl
chain packing disorder (P , 0.001, N 5 6). B: The order parameter, S, calculated from the model-independent analysis of the
anisotropy decays in terms of the sum of three exponential decays.
The higher S value for the membranes from AY9944-treated
animals, compared with controls, indicates increased orientational
order of DPH (P , 0.001, N 5 6). Error bars indicate 6 SD.

Cv, and this parameter was significantly reduced in the
treated ROS membranes, relative to controls (Fig. 4A).
Increased order in the treated ROS membranes is also
reported by the model-independent analysis, which summarizes orientational order as indicated by the order
parameter, S (Fig. 4B). The relative changes in both
parameters may appear to be modest (range, 6–13%),
but both parameters indicate a substantial increase in acyl
chain order (reduced fluidity) in the core of the membrane. For a biological membrane at 37°C, a similar reduction in fluidity would require an increase in Chol from
12 mol% to ?30 mol%, or a reduction in temperature
from 37°C to ?25°C. A comparable reduction of fv was
observed in ROS membranes from rats raised on an n3deficient diet, which caused a substantial reduction in
the levels of 22:6n3 (30).
A second indication that the core of the bilayer is less
fluid in the ROS membranes from AY9944-treated rats is
the reduced rate of DPH rotational motion in these membranes. Changes in both the diffusion constant for DPH
rotation about its long axis, Dperp, from the BRD analysis
(Fig. 5A), and the average rotational time constant, ,w.,
from the empirical analysis (Fig. 5B) demonstrate that
probe motion is slower in the treated ROS membranes.
Both parameters of rotational motion change about
15%, but significant perturbations, such as a 2.5-fold increase in Chol or a 10–15°C reduction in temperature,
would be required to produce a comparable reduction
in probe motion.

Fig. 5. Measures of DPH rotational motion obtained from analysis
of DPH fluorescence anisotropy decays. A: The diffusion constant
for DPH rotation about its long axis, Dperp, from the BRD model
analysis. The smaller value in ROS membranes from the AY9944treated animals, compared with controls, indicates slower DPH
rotation (P 5 0.006, N 5 6). B: The weighted average of the
three empirical rotational time constants, ,w., from the model-independent analysis. The higher value for membranes from
AY9944-treated animals, compared with controls, indicates slower
DPH rotation (P 5 0.006, N 5 6). Error bars indicate 6 SD.

AY9944 treatment alters regenerability of rhodopsin
The changes in the membrane environment that occur
at 3 months are concomitant with the previously described
retinal degeneration in this model (8), which also entails
defective phototransduction. To determine whether
AY9944-induced alterations in membrane dynamics are
correlated with a parameter pertinent to phototransduction (e.g., rhodopsin function), we next analyzed the ability of the bleached photopigment (opsin) to recombine
with exogenously supplied 11-cis retinal chromophore to
regenerate rhodopsin in vitro, using ROS membranes
from control versus AY9944-treated rats. As shown in
Fig. 6, at 1 postnatal month, no significant decrease in
rhodopsin regenerability was observed between ROS obtained from control and AY9944-treated rat retinas (95 6
2.6% in controls, 92 6 1.5% in AY9944-treated retinas).
The total extent and rate of rhodopsin regeneration, however, were decreased significantly by 3 postnatal months as
a function of AY9944 treatment (65 6 1.5% regenerability)
relative to controls (82 6 3.0% regenerability).

DISCUSSION
In the present study, we have demonstrated that perturbation of sterol biosynthesis by use of the distal pathway
inhibitor AY9944 profoundly alters both ROS membrane
sterol composition as well as fatty acid composition, relative to age-matched control rats, in a time-dependent manner. Concomitantly, as expected, the physical properties of
the membranes are altered; notably, there is a significant
reduction in membrane fluidity by 3 months, as measured
by use of fluorescent fatty acid probes. Also, the ability of
opsin to combine with its 11-cis retinal chromophore to

Fig. 6. Rhodopsin regeneration in ROS membranes from control
and AY9944-treated rats. Values expressed as percent regeneration,
shown as a function of time ROS membranes were incubated with excess 11-cis retinal at 37°C. Comparison of values from 1 month-old
control (open circles) versus AY9944-treated rats (filled circles)
shows no statistically significant difference (N 5 3). In contrast,
comparison of values from 3 month-old control (open squares) and
AY9944-treated rats (filled squares) showed a statistically significant
difference (P 5 0.0006, N 5 3, at 24 h). Error bars indicate 6 SD.
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regenerate rhodopsin is compromised by 3 months of
treatment. Interestingly, although the changes in membrane sterol and fatty acid composition are substantial
even by 1 month of treatment, there is no retinal degeneration or profound electrophysiological deficits at this
stage in the treatment time course (7), nor is rhodopsin
regeneration affected. By 3 months of AY9944 treatment,
however, ROS sterol and fatty acid composition are even
more deranged, most notably with the profound (.40%)
loss in DHA content, and rhodopsin regenerability is significantly compromised. This stage of treatment corresponds
to the progression to marked retinal degeneration, particularly rod photoreceptor degeneration and death, as well as
defective rod and cone visual function (8). The question
arises as to whether the observed effects on membrane
fluidity and visual pigment regenerability are due primarily
to the altered sterol composition or to the altered fatty acid
composition of the ROS membranes. To answer this question, one must consider in further detail the changes in
these two distinct lipid classes.
Because the absolute recovery efficiency of ROS membranes varies from one preparation to the next, one
cannot confidently make direct comparisons of absolute
values for sterol mass between membrane preparations.
However, if one normalizes the total sterol mass to total
fatty acid mass on a molar basis, a comparison can be
made. Using the empirically determined values for the
total sterol and fatty acid content of ROS membranes from
both AY9944-treated and control rats, we calculate a sterol:
fatty acid mole ratio of 0.062 (612%). This is in good
agreement with published values for both the Chol content (?8–10 mol% of total ROS lipid) and phospholipid
content (?85–90 mol% of total ROS lipid, and 65–
75 mol of phospholipid per mole of rhodopsin) of ROS
membranes, (as reviewed in Ref. 29). To a first approximation (excluding plasmalogens), each glycerophospholipid
molecule contains two acyl chains. Hence, if the Chol:
phospholipid mole ratio is approximately 1:9 in ROS membranes, the Chol:fatty acid mole ratio should be about
1:18, or 0.056. The fact that this ratio is the same in ROS
membranes from both normal control and AY9944-treated
rats further reveals that the total sterol mass in ROS membranes is unaffected by AY9944 treatment (i.e., there is no
net loss of sterol mass in the membranes). Hence, there is
a one-for-one molecular replacement of Chol with 7DHC
under the conditions employed. However, the chemical
composition of the membrane sterol pool is dramatically
and progressively altered: by 1 month of AY9944 treatment,
the 7DHC:Chol mole ratio is 3:5, whereas by 3 months, it is
5:6; in contrast, Chol is essentially the only sterol present in
normal rat ROS membranes at any age.
The impact of sterol chemistry on the structure and
function of biological membranes has been a subject of extensive investigation over the years (as reviewed in Refs. 31,
32). In sum, there do not appear to be uniformly applicable rules to predict with certainty the consequences
of replacing Chol with sterols of different structures, such
as 7DHC; rather, the impact of such changes tends to be a
function of the particular sterol and the biological system
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being examined. However, recent studies from our lab
using model membrane systems suggest that 7DHC has
physical properties very similar to those of Chol, including
packing densities and molecular volumes in mixed sterolphospholipid monolayers (Langmuir films) (33, 34).
These findings, in conjunction with the fact that sterols account for ,10 mol% of the total lipid in ROS membranes
(29), would tend to support the conclusion that altered
sterol composition is not a major factor in the observed
changes in membrane fluidity or rhodopsin regenerability.
Our results obtained with fluorescent probe measurements demonstrate that the hydrophobic core of the
ROS membranes becomes more ordered (less fluid), as
has been previously reported in cases in which there is
a substantial decrease in the polyunsaturated fatty acid
(e.g., 22:6n3) content of the ROS membrane (30). In a
study of the effects of dietary n3 deficiency, a similar
increase in the acyl chain order reported by DPH in
ROS membranes was accompanied by a 50% increase in
the time required for transducin binding to light-activated
rhodopsin and a 3-fold decrease in light-stimulated phosphodiesterase activity (30). An earlier study of the relationship between acyl chain packing, as reported by fv, and
formation of the light-activated conformation metarhodopsin II indicates that the decrease in fv found in the
present study would depress metarhodopsin II by 25–
30% (35). Increasing Chol in ROS disk membranes from
12% to 30% produced a reduction of fv comparable to
treatment with AY9944, and this was accompanied by a
20% reduction in metarhodopsin II (36). In all of these
earlier studies, increased acyl chain order in the membrane hydrophobic core was accompanied by an increase
in DPH fluorescence lifetime, indicating increased order
in the head group region. In the present study, the decreased order in the headgroup/interfacial region reported by both DPH and cPA strongly suggests that
treatment with AY9944 produces a unique set of changes
in the physical properties of ROS membranes. In the core
of the membrane, these changes appear to be dominated
by the marked reduction in the number of 22:6n3 acyl
chains, consistent with the increased order and decreased
motion of DPH (Figs. 4, 5, respectively). However, the
changes reported by cPA (Fig. 3) and DPH fluorescence
lifetime suggest additional significant modifications of
membrane architecture. This simultaneous decrease in
fluidity in the membrane core and slight increase in fluidity in the headgroup/interfacial region may be due to the
particular molecular species that lost 22:6n3 acyl chains, or
a change in lipid lateral phase organization.
Our fatty acid analyses (Fig. 1) showed that although
there were several ROS fatty acyl species that exhibited
statistically significant altered levels, comparing AY9944treated rats to age-matched controls, the magnitude
of these changes tended to be rather modest for most
species, particularly for saturated and monounsaturated
acyl chains. The spectroscopic results obtained with cPA
indicate that these changes were not substantial enough
to appreciably alter membrane fluidity after only 1 month
of AY9944 treatment. However, more-dramatic alterations

in ROS membrane fatty acid composition were observed
by 3 months of AY9944 treatment, relative to age-matched
controls. Notably, by normalizing the 22:6n3 content to
that of 18:0, an invariant fatty acid (Table 2), there was a
?41 mol% loss of 22:6n3, compared with controls. This
finding is consistent with the results obtained recently by
lipidomic analysis of whole retinas from AY9944-treated
and control rats, where the most notable alteration in
retinal glycerophospholipids (phosphatidylethanolamine,
phosphatidylcholine, and phosphatidylserine) was a profound loss in molecular species containing 22:6n3 with
AY9944 treatment (9). Clearly, the magnitude of this
change was sufficient to cause appreciable changes in
the physical properties of the ROS membranes (Figs. 3–5).
Increased order in the membrane core and simultaneous decreased order in the headgroup and interfacial
regions is somewhat unique and suggests that other
changes in membrane composition also play a role in altering the membrane. Significantly large alterations in the
protein-to-lipid ratio would result in marked differences
in the physical properties of the membranes, which would
be readily detectable by the spectroscopic methods employed here. In the case of the ROS membrane, the visual
pigment rhodopsin is estimated to account for at least 90%
of the total integral membrane protein, and the lipid-toprotein mass ratio is approximately 1:1 (29). Rhodopsin
packing density also has been correlated with alterations
in membrane function (assessed by rhodopsin activation,
which impacts efficiency of the phototransduction cascade) (37, 38). However, our analyses showed that there
was no significant alteration in the opsin-to-phospholipid
ratio of ROS from AY9944-treated rats, compared with
age-matched controls; hence, the protein packing density
in ROS membranes was unaffected by AY9944 treatment.
In fact, a reduction in opsin levels, and concomitant reduction in protein packing density, would be predicted to
cause an increase in membrane fluidity, which clearly
was not observed here.
It is important to note that although no histological
degeneration or apparent loss in rod or cone electrophysiological responsiveness was observed in the AY9944-induced rat model of SLOS after 1 month of treatment,
there was an appreciable and statistically significant delay
in the timing of those photoresponses (i.e., increased implicit times) (7). The implicit time is related to the efficiency of the phototransduction cascade operative in the
photoreceptor cell, involving both the protein components organized within and at the surface of the ROS disk
membranes as well as the cyclic nucleotide-gated ion channels located in the ROS plasma membrane (39). Hence, it
is apparent that even the relatively modest (in absolute
magnitude) changes in the fatty acid profile of the ROS
membranes that occur by 1 month of AY9944 treatment
have some biological impact at the membrane level,
although not enough to cause overt cellular dysfunction
or degeneration. The retina requires high levels of DHA
for optimal function, particularly with regard to supporting photoreceptor viability and electrophysiological competence (29). ROS membranes in which the DHA

content has been significantly reduced compared with normal levels exhibit slower than normal photoresponses,
which correlates with impaired activation of transducin,
the cognate G-protein and key player in the phototransduction cascade (30). It is tempting to speculate that faced
with a metabolic insult (such as disrupting normal Chol
biosynthesis), the cell responds by globally remodeling
its membrane lipidome in an effort to preserve cellular
integrity and function, including preservation of membrane fluidity that is critical to the function of a host of
membrane-associated enzymes, receptors, and ion channels (40). However, although the retinal photoreceptor
cells may be able to tolerate this level of stress for at least
1 month, eventually they lose physiological competence
and cellular integrity, undergoing degeneration and cell
death by 3 months of exposure to AY9944 (8, 15). At that
point, rod and cone electrophysiology and structure are
severely compromised, and this also correlates temporally
with the dramatic losses in the DHA content of ROS membranes documented in this study, as well as those recently
reported under virtually identical conditions for whole
retina (9). Notably, it is at 3 months of AY9944 treatment
that we also observe altered membrane properties, as assessed by the behavior of fluorescent probes added in
small amounts to isolated ROS membranes, which also
are consistent with the more dramatic changes in fatty
acid composition, particularly DHA.
Herein, we show for the first time that one pathologic
consequence of decreased Chol biosynthesis in a rat model
of SLOS is reduced rhodopsin regenerability. It should be
noted that our in vitro studies of rhodopsin regeneration
were performed in the presence of excess exogenous 11-cis
retinal; hence, the decreased regeneration cannot be due
to insufficient retinoid availability. Reduction in the regenerability of rhodoposin also would be expected to negatively impact the efficiency of phototransduction and,
hence, photoreceptor function, consistent with our prior
in vivo observations with the SLOS rat model (7, 8, 15).
We speculate that opsinʼs ability to assume a conformational state requisite for optimal regeneration is impaired
as a consequence of alterations in membrane lipid composition and biophysical properties (e.g., fluidity), such
alterations being more extensive by 3 months than by
1 month of exposure of rats to AY9944. This may represent
a threshold phenomenon: beyond some level of deviation
from normal membrane composition and biophysical
properties, opsin regenerability is compromised, whereas
deviations below that level (even though not normal) are
apparently tolerable with respect to opsin regenerability.
A similar hypothesis (the molecular spring model) was
put forward by Dratz and Holte (41) to explain diminished
rhodopsin bleaching kinetics in the presence of altered
levels of Chol and DHA. Whether an analogous mechanism involving lipid–protein interactions in rhodopsin
regeneration is at play here is unknown. However, we
suggest that alterations in membrane composition that
decrease headgroup/interfacial order and increase hydrocarbon order also result in decreased efficiency of
rhodopsin regeneration, consistent with the observed
ROS membrane fluidity in the SLOS rat model
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electrophysiological defects in the SLOS rat model and in
human SLOS patients, and may contribute to long-term
retinal degeneration due to the inability of the retina to
adapt to the continuous exposure to light.
With the exception of our recent studies with the SLOS
rat model (9), the implication of a linkage between
disrupted sterol biosynthesis and altered fatty acid metabolism, particularly in association with SLOS, has never been
proposed. We have proposed (9) that cross-talk between
sterol and fatty acid metabolism may explain the results
observed with the AY9944-induced rat model, and that additional metabolic compromise beyond the primary defect
in sterol biosynthesis may contribute to the pathology of
SLOS. The exact mechanism by which AY9944 (which
allegedly is a selective inhibitor of DHCR7 in the sterol
pathway) perturbs fatty acid metabolism remains to be elucidated. Interestingly, altered membrane fluidity has been
reported recently by one of us (K.B-B.) in a study of skin
fibroblasts obtained from SLOS patients, using the same
spectroscopic techniques as employed in the current study
(42). Although this finding had been considered only
within the context of altered membrane sterol composition, our results suggest the possibility that additional
changes in the steady-state fatty acid composition of the
fibroblast membranes also may underlie the observed
alterations in membrane fluidity.
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